Materias dentro de su búsqueda.
Mostrando 5,481 - 5,500 Resultados de 6,403 Para Buscar '"European Union"', tiempo de consulta: 0.22s Limitar resultados
  1. 5481
    “…In addition to renewable and cost-effective energy production, AD has emerged in the European Union as an environmentally friendly model of bio-waste valorisation and nutrient recycling. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A year of monitoring 20 mesophilic full-scale bioreactors reveals the existence of stable but different core microbiomes in bio-waste and wastewater anaerobic digestion systems
  2. 5482
    “…BACKGROUND: Nintedanib in combination with docetaxel is approved in the European Union and other countries for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy, based on the overall survival findings of Phase III LUME-Lung 1 study. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study
  3. 5483
    “…Thus, risk factors for asthma should be sought in both parents and before conception. FUNDING: European Union (Horizon 2020, GA-633212).…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A three-generation study on the association of tobacco smoking with asthma
  4. 5484
    “…Trial registration EMA: European Union Clinical Trials Register: (https://www.clinicaltrialsregister.eu/ctr-search/search?…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
  5. 5485
    “…One of the purposes of the European Network on ME/CFS (EUROMENE; European Union-funded COST Action; Reference number: 15111) is to address this gap in knowledge. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review
  6. 5486
    “…In 2016, Campylobacter was the most commonly reported gastrointestinal bacterial pathogen in humans in the European Union with 246,307 reported cases. Of these cases, 83.6% were Campylobacter jejuni. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Feed Choice Led to Higher Protein Intake in Broiler Chickens Experimentally Infected With Campylobacter jejuni
  7. 5487
    “…The two most common data sharing policy conditions that prevented sharing of data for published results were the exclusion of studies that had ongoing follow-up of the published results and the exclusion of studies of medicines that have not yet achieved regulatory approval in the USA and the European Union. CONCLUSIONS: Fifteen percent of the sampled clinical trials were available for data sharing 2 years after publication of primary results of the trial. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability
  8. 5488
    “…BACKGROUND: European legislation dictates that pig tail docking is not allowed to be performed routinely (European Union. Council Directive 2008/120/EC of 18 December 2008 laying down minimum standards for the protection of pigs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    ‘Phasing out pig tail docking in the EU - present state, challenges and possibilities’
  9. 5489
    “…FTD/TPI was approved in the European Union (EU) in April 2016 and launched on the German market in August 15, 2016. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
  10. 5490
    “…DISCLOSURES: V. Tam, European Union’s Seventh Framework Programme: Grant Investigator, Research grant.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1410. Novel Framework to Compare the Effectiveness of Tazobactam, Relebactam and Avibactam Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
  11. 5491
    por Brzezinski, Michal
    Publicado 2019
    “…The data come from longitudinal 2011 European Union Statistics on Income and Living Conditions (EU-SILC) database. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    What accounts for the rise of low self-rated health during the recent economic crisis in Europe?
  12. 5492
    “…METHODS AND RESULTS: The EU‐CERT‐ICD is a prospective investigator‐initiated non‐randomized, controlled, multicentre observational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischaemic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Rationale and design of the EU‐CERT‐ICD prospective study: comparative effectiveness of prophylactic ICD implantation
  13. 5493
    “…A total of 300 patients will be enrolled at approximately 30 sites within the European Union. Patients are randomised to receive active treatment (2 and 4 mg/kg adrecizumab) or placebo, in a 1:1:2 ratio. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)
  14. 5494
    “…In 2018, a record number (12) of antibodies (erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), burosumab (Crysvita), lanadelumab (Takhzyro), caplacizumab (Cablivi), mogamulizumab (Poteligeo), moxetumomab pasudodox (Lumoxiti), cemiplimab (Libtayo), ibalizumab (Trogarzo), tildrakizumab (Ilumetri, Ilumya), emapalumab (Gamifant)) that treat a wide variety of diseases were granted a first approval in either the European Union (EU) or United States (US). As of November 2018, 4 antibody therapeutics (sacituzumab govitecan, ravulizumab, risankizumab, romosozumab) were being considered for their first marketing approval in the EU or US, and an additional 3 antibody therapeutics developed by Chinese companies (tislelizumab, sintilimab, camrelizumab) were in regulatory review in China. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibodies to watch in 2019
  15. 5495
    por Meyer, Alain, Scirè, Carlo Alberto, Talarico, Rosaria, Alexander, Tobias, Amoura, Zahir, Avcin, Tadej, Barsotti, Simone, Beretta, Lorenzo, Blagojevic, Jelena, Burmester, Gerd, Cavazzana, Ilaria, Cherrin, Patrick, Damian, Laura, Doria, Andrea, Fonseca, João Eurico, Furini, Federica, Galetti, Ilaria, Houssiau, Frederic, Krieg, Thomas, Larosa, Maddalena, Launay, David, Campanilho-Marques, Raquel, Martin, Thierry, Matucci-Cerinic, Marco, Moinzadeh, Pia, Montecucco, Carlomaurizio, Moraes-Fontes, Maria Francisca, Mouthon, Luc, Neri, Rossella, Paolino, Sabrina, Piette, Yves, Rednic, Simona, Tamirou, Farah, Tincani, Angela, Toplak, Natasa, Bombardieri, Stefano, Hachulla, Eric, Mueller-Ladner, Ulf, Schneider, Matthias, Smith, Vanessa, Vieira, Ana, Cutolo, Maurizio, Mosca, Marta, Cavagna, Lorenzo
    Publicado 2019
    “…It has been performed in the framework of the European Reference Network on rare and complex connective tissue and musculoskeletal diseases (ReCONNET), a network of centre of expertise and patients funded by the European Union’s Health Programme. Fourteen original CPGs were identified, notably recommending that: i) extra-muscular involvements should be assessed; ii) corticosteroids and methotrexate or azathioprine are first-line therapies of IIMs. ii) IVIG is a treatment of resistant-DM that may be also used in other resistant-IIMs; iii) physical therapy and sun protection (in DM patients) are part of the treatment; v) tumour screening for patients with DM include imaging of chest, abdomen, pelvis and breast (in woman) along with colonoscopy (in patients over 50 years); vi) disease activity and damages should be monitor using standardised and validated tools. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
  16. 5496
    “…BACKGROUND: In 2011 there was a strengthening of European Union (EU) legislation on the licencing of herbal products which, in the UK, resulted in the introduction of the Traditional Herbal Registration (THR) scheme. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    What has been the impact of the Traditional Herbal Registration (THR) scheme in the UK on information provided with herbal products bought over the counter?
  17. 5497
    “…Antibiotic growth promoters have been banned by European Union and restricted by other countries in livestock production due to the public concern about food safety and antibiotic resistance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dietary β-Sitosterol Improves Growth Performance, Meat Quality, Antioxidant Status, and Mitochondrial Biogenesis of Breast Muscle in Broilers
  18. 5498
    “…This was a phase 3, multicenter, randomized, double-blind, parallel-group equivalence trial of MYL-1401H vs European Union–sourced reference pegfilgrastim. Patients with newly diagnosed stage II/III breast cancer eligible to receive (neo) adjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide every 3 weeks for 6 cycles were enrolled and randomized 2:1 to 6 mg of MYL-1401H or reference pegfilgrastim 24 h (+ 2-h window after the first 24 h) after the end of chemotherapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
  19. 5499
    “…The Scholarly Concentrations program at Johns Hopkins has been transformed to a program at Bezmiâlem in Istanbul, the first program outside North America or the European Union. When designing these programs, one must consider the context, logistics, student engagement, and outcomes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Transforming a U.S. scholarly concentrations program internationally: lessons learned
  20. 5500
    “…However, total concentration of inorganic arsenic in most of investigated rice samples was below the maximum residual level according to US-FDA and European Union standards.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Speciation Analysis of Arsenic Compounds by High-Performance Liquid Chromatography in Combination with Inductively Coupled Plasma Dynamic Reaction Cell Quadrupole Mass Spectrometry: Application for Vietnamese Rice Samples
Herramientas de búsqueda: RSS